01/24/23 7:00 AMAMEX : CANF clinical triallow floatCan-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been FiledData show significant anti-cancer effect in pancreatic carcinoma as a monotherapy and an additive effect when combined with gemcitabine, the standard-of-care chemotherapy for pancreatic cancer Namodenoson’ s excellent safety profile and its ability to directly inhibit the growth of pancreatic tumors present its potential as an effective drug for the...RHEA-AIneutral
01/11/23 9:04 AMAMEX : CANF offeringlow floatCan-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private PlacementCan-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that it has entered into definitive agreements for the purchase and sale of 1,000,000 of the Company’ s American Depositary Shares, at a purchase price of $5.50...RHEA-AIneutral
01/10/23 7:00 AMAMEX : CANF low floatCan-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to FollowCan-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today...RHEA-AIvery positive
12/30/22 4:30 PMAMEX : CANF low floatCan-Fite Announces ADS Ratio ChangeCan-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that the Company will change the ratio of its American Depositary Shares to ordinary shares from one ADS representing thirty ordinary shares to a new ratio of...RHEA-AIneutral
12/28/22 7:00 AMAMEX : CANF low floatCan-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver CancerResults to be shared at Biotech Showcase during JP Morgan conference week in San Francisco and at BI0-CEO in New York An advanced CPB liver cancer patient remains clear of cancer 6 years following treatment with Namodenoson While CPB patients are typically excluded from liver cancer clinical studies due to low expected response rates,...RHEA-AIvery positive
12/08/22 7:00 AMAMEX : CANF clinical triallow floatCan-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ OsteoarthritisCan-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced progress achieved in the development of Piclidenoson for` the treatment of...RHEA-AIpositive
11/25/22 7:00 AMAMEX : CANF earningslow floatCan-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical UpdateCan-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2022. The patient was in the Namodenoson arm of the Phase II study and continued treatment with...RHEA-AIneutral
11/02/22 7:15 AMAMEX : CANF low floatCan-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in BostonThe Summit will host industry drug development experts, all in the dermatology arena, who will present their technologies, exchange views and look at potential collaborations and partnerships. Phase III COMFORT study successfully met its primary efficacy endpoint with Piclidenoson showing a safety profile similar to placebo and better tolerated than...RHEA-AIneutral
10/25/22 7:00 AMAMEX : CANF low floatCan-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that a poster entitled“ Complete Response Induced by Namodenoson, an A3...RHEA-AIneutral
10/13/22 7:00 AMAMEX : CANF conferenceslow floatCan-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming ConferenceCan-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today the Company’ s CEO Dr. There is currently no U.S. FDA approved treatment for NASH, an addressable pharmaceutical market estimated to reach $35-$40 billion by 2025...RHEA-AIneutral